Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs CVS Health Corp — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.53, while CVS Health Corp trades at $104.26 (market cap $133.12B). The key difference: CVS Health Corp pays a 2.55% dividend while Global X Artificial Intelligence & Technology ETF pays none, and CVS Health Corp is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | CVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $104.81 |
52-Week Low | $43.28 | $58.75 |
Market Cap | — | $133.12B |
Enterprise Value | — | $199.66B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
CVS Health trades at $104.33, down slightly on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates, including a recent Q1 2026 beat, and benefits from positive sentiment around strategic initiatives like GLP-1 drug access. Revenue growth remains solid, though net margins are thin. The current price sits just below the consensus price target of $106.86.
The outlook for CVS is positive, driven by earnings momentum and strategic positioning in healthcare services. Key opportunities include margin expansion potential and market share gains. Risks involve intense competition, regulatory pressures on healthcare pricing, and the company's significant debt load, which requires careful management of cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
